Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance

Clin Infect Dis. 2006 Feb 1;42(3):408-10. doi: 10.1086/499369. Epub 2005 Dec 27.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Alkynes
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Benzoxazines
  • Cyclopropanes
  • Cytochrome P-450 CYP2B6
  • Drug Resistance, Viral / genetics*
  • Genotype
  • HIV Infections / drug therapy
  • HIV Infections / genetics
  • Humans
  • Oxazines / adverse effects*
  • Oxazines / blood
  • Oxazines / pharmacokinetics*
  • Oxazines / therapeutic use
  • Oxidoreductases, N-Demethylating / genetics*
  • Oxidoreductases, N-Demethylating / metabolism
  • Phenotype
  • Polymorphism, Genetic / genetics*

Substances

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • Oxazines
  • Aryl Hydrocarbon Hydroxylases
  • CYP2B6 protein, human
  • Cytochrome P-450 CYP2B6
  • Oxidoreductases, N-Demethylating
  • efavirenz